Hidehiko Okazawa, Tomoya Uehara, Ichiei Kuji, Tatsuya Higashi, Mana Yoshimura
{"title":"[第42次放射性药品不良反应调查报告(2019年第45次调查)]。","authors":"Hidehiko Okazawa, Tomoya Uehara, Ichiei Kuji, Tatsuya Higashi, Mana Yoshimura","doi":"10.18893/kakuigaku.rp.2131","DOIUrl":null,"url":null,"abstract":"<p><p>This survey was performed in order to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2019 in Japan. It was based on responses to questionnaires sent to nuclear medicine institutions. Replies were obtained from 1,003 institutions out of 1,213 to which the questionnaire had been sent. A total of 1,037,568 radiopharmaceutical administrations were reported. Eighteen cases of adverse reactions were reported. The incidence of adverse reactions per 100,000 cases was 1.7. No case of defective products was reported.</p>","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[The 42nd Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 45th Survey in 2019)].\",\"authors\":\"Hidehiko Okazawa, Tomoya Uehara, Ichiei Kuji, Tatsuya Higashi, Mana Yoshimura\",\"doi\":\"10.18893/kakuigaku.rp.2131\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This survey was performed in order to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2019 in Japan. It was based on responses to questionnaires sent to nuclear medicine institutions. Replies were obtained from 1,003 institutions out of 1,213 to which the questionnaire had been sent. A total of 1,037,568 radiopharmaceutical administrations were reported. Eighteen cases of adverse reactions were reported. The incidence of adverse reactions per 100,000 cases was 1.7. No case of defective products was reported.</p>\",\"PeriodicalId\":17738,\"journal\":{\"name\":\"Kaku igaku. The Japanese journal of nuclear medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kaku igaku. The Japanese journal of nuclear medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18893/kakuigaku.rp.2131\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kaku igaku. The Japanese journal of nuclear medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18893/kakuigaku.rp.2131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[The 42nd Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 45th Survey in 2019)].
This survey was performed in order to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2019 in Japan. It was based on responses to questionnaires sent to nuclear medicine institutions. Replies were obtained from 1,003 institutions out of 1,213 to which the questionnaire had been sent. A total of 1,037,568 radiopharmaceutical administrations were reported. Eighteen cases of adverse reactions were reported. The incidence of adverse reactions per 100,000 cases was 1.7. No case of defective products was reported.
期刊介绍:
The main scope of JSNM is the appropriate development of the application of radioactive substances and stable nuclides in medicine. Towards this scope, JSNM promotes the exchange of idea and information, and researches in nuclear medicine. JSNM are interested in the international collaboration for the development of nuclear medicine. Through the activities, JSNM contributes to the medicine, as well as humanity, not only in Japan but also in any countries over the world.